Dr. Jeffrey Schneider received his undergraduate degree from Brown University and his medical degree from Yale University’s School of Medicine. He continued his clinical training as an internal medicine resident at New York University School of Medicine and as a hematology and medical oncology fellow at Memorial Sloan-Kettering Cancer Center where he remained on faculty for several years in the medical division of breast and gynecologic oncology. In 1994, Dr Schneider joined the faculty of Winthrop University Hospital where he remains to the present time. At Winthrop, Dr Schneider has taken on diverse academic roles as head of the hospital’s autologous stem cell transplantation program as well as director of its multidisciplinary center of excellence in lung cancer. At the same time, Dr Schneider maintains an active interest in all aspects of solid tumor oncology. He has numerous publications and lectures widely in this field.
Description of Research Interests/Activities
Tumor Biomarkers in Clinical Practice
• ERCC1 in lung cancer – impact of laboratory variations
• Interleukin-6 – predictive utility for EGFR antagonist therapies
• Oncotype DX in breast cancer – why and how it influences adjuvant treatment
Lung Cancer Treatment
• Combining anti-Interleukin-6 antibody therapy with EGFR antagonists
• Principle Investigator on numerous lung cancer treatment protocols
Basic Lung Cancer Research
• In collaboration with laboratory of molecular therapeutics and signal transduction at Cold Spring Harbor
Areas of Experience
Research Team Members
Raffaella Sordella, PhD, Cold Spring Harbor Laboratories
Daniel Khalil, PhD, Stony Brook University medical student
Vatsala Kirtani, MD, Winthrop Hem/ Onc fellow
Nosha Farhadfar, MD, Winthrop Internal Medicine resident
Abirami Sivapiragasam, MD, Winthrop Internal Medicine resident
Lorna Ogden, MD, Winthrop Pathology resident
Matthew Geller, DO, Winthrop Pathology resident
Clinical Practice and Interests
In addition to maintaining a clinical practice encompassing the full spectrum of hematology and medical oncology, Dr. Schneider has strong related interests in cancer screening, clinical decision making and physician education.
Schneider JG, Farhadfar N, Sivapiragasam A, Geller M, Ogden L, Selbs E, “Commercial laboratory testing of ERCC-1 testing in non-small cell lung cancer: clinical implications of discordant results,” Proc Am Soc Clin Oncol, in press 2011
Khalil D, Schneider JG, “Role of Oncotype 21 Gene Assay and Adjuvant! Online in Breast Cancer Adjuvant Treatment Decisions,” Proc 33rd Annual San Antonio Breast Cancer Symposium, San Antonio, TX. Poster P2-09-38, December 2010.
Epstein NE, Drexler S, Schneider J, “Clear Cell Meningioma of the Cauda Equina in an Adult: Case Report and Literature Review,” J Spin Disord Tech 18(6), 539-543, 2005
Zacharski LR, Orenstein DL, Gabazza EL, Gabazza C, Brugarolas A, Schneider J, “Treatment of Malignancy by Activation of the Plasminogen System,” Semin Thromb Hemost 28(1), 5-18, 2002.
Vintila CD, Schneider J, Pollack S, Farley T, “Heparin Anticoagulation Promotes CD 34 Positive Progenitor Cell Mobilization into the Peripheral Blood,” Proc Am Soc Clin Oncol, 20: Abs #46, 2001 and Poster Presentation & Poster Discussion Session, May 2001
Schneider JG and Gibson LE: “Adjuvant Therapy Following Radical Hysterectomy,” In: Cervical Cancer and Preinvasive Neoplasia, Hoskins WJ and Rubin SC (eds), Philadelphia, PA, Lippincott – Raven Publishers, 1996.
Schneider JG, Crown J, Wasserheit C, Kritz A, Reich L, Moore MAS, “Factors Affecting the Mobilization of Primitive and Committed Hematopoietic Progenitors in the Peripheral Blood of Cancer Patients.” Bone Marrow Transplantation 14: 877-884, 1994.
Schneider JG: “Intraperitoneal Chemotherapy.” Obstetrics and Gynecology Clinics of North America, 21 (1): 195-212, 1994
Schneider JG: “Hematopoietic Growth Factors: Rationale and Use in Gynecologic Oncology.” Prin Pract Gynecol Oncol Updates. 1(5): 1-12, 1993.
Muench MO, Schneider JG, Moore MAS, “Interactions Among Colony Stimulating Factors, IL-1, IL-6, and cKit Ligand in the Regulation of Primitive Murine Hematopoietic Cells,” Exp Hem, 20: 339-349, 1992.
Proc Am Soc Clin Oncol